TPG Capital, the US private equity firm, has completed its acquisition of Optum UK, the company that supplies electronic patient record systems to more than half of general practices in England. The deal closed on 13 March 2026 at a reported price of $400 million, equivalent to approximately £293.5 million, though earlier reports from January had placed the expected transaction value between £1.2 billion and £1.4 billion. The discrepancy has not been publicly explained by either party.

Optum UK is the parent company of EMIS, a Leeds-headquartered software provider whose systems manage patient records, appointment bookings and prescription processing across more than 4,000 GP surgeries in England. The business was itself acquired by UnitedHealth Group's Optum division in October 2023 for around £1.2 billion, meaning it has now changed hands twice in under three years. The latest sale is part of a broader divestiture strategy under UnitedHealth's new chief executive, Stephen Hemsley, following a sharp decline in the group's share price.

The English primary care IT market operates as an effective duopoly. EMIS and TPP's SystmOne together account for the overwhelming majority of GP IT provision in England, a structure that senior government health advisers have previously described as a barrier to competition and innovation. Repeated attempts by NHS policymakers to open the market to new entrants have had limited effect. NHS England's approval of Medicus Health as a new GP IT supplier in June 2025, described at the time as the first new entrant in 25 years, represents the most tangible recent shift. French healthtech firm Doctolib subsequently acquired Medicus, adding an international dimension to what has historically been a domestically concentrated market.

For the NHS, the change of ownership raises questions about data stewardship. EMIS systems hold clinical records for millions of patients in England, and the transition places that data under the management of a firm whose primary interest is financial return. 

A spokesperson for Optum said TPG's involvement would help strengthen the business's ability to support customers and develop what they described as next-generation capabilities, with a continued focus on delivering trusted systems aligned with NHS strategic priorities. TPG has not elaborated publicly on its operational plans for the business, though sources have previously suggested the firm may seek to combine Optum UK with Nextech, a US-based electronic medical records provider TPG already owns.

The acquisition is likely to prompt scrutiny of existing NHS digital health contracts. When UnitedHealth acquired EMIS in 2023, the deal required approval from the Competition and Markets Authority following a Phase 2 review that received a large number of concerns from stakeholders including NHS Digital.

 It is not yet clear whether the CMA or NHS England intends to conduct a formal review of the new ownership arrangement, or whether existing contractual frameworks are sufficient to ensure continuity of service and data protection obligations. Neither body had issued a public statement on the transaction at the time of publication.

Critics within the medical and health technology communities have long argued that the concentrated structure of the GP IT market leaves the NHS with inadequate leverage when negotiating terms with its main suppliers. The entry of a private equity firm deepens that concern for some, given the sector's general orientation toward cost efficiency and returns over a defined investment horizon. Proponents of the deal point to the potential for increased capital investment in cloud infrastructure and AI integration, areas where NHS primary care technology has historically lagged.

The acquisition of EMIS by Optum in 2023 was conditionally cleared by regulators. Whether the current transaction triggers a comparable level of oversight remains to be seen. What is not in dispute is the scale of what has changed hands: a software platform embedded in the daily clinical operations of tens of millions of patient interactions across England, now managed by a private equity firm based in San Francisco.